FTH logo

Faeth Therapeutics, Inc.

FTH
Healthcare|Biotechnology|US
$22.05
+2.13 (+10.69%)
DCF Value
$5.16
Tangible Book / Share
$6.50
Cash / Share
$6.76

About

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Stock Price

+136.1%(1Y)
1M
-13.9%
3M
-9.6%
6M
-5.8%
YTD
+106.7%
1Y
+129.4%
3Y
+43.0%
5Y
-87.5%

Pipeline Summary

6 total trials
2
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
Withdrawn: 1Recruiting: 2Completed: 1Terminated: 2

Active Trials (2)

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
NCT07558733HR+ HER2- Breast Cancer
Phase 1Phase 2Recruiting
Enrollment: 32 participants
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
NCT06463028Endometrial Cancer
Phase 2Recruiting
Enrollment: 40 participants

Key Facts

Market Cap$568.4M
Employees29 (+107% YoY)
CEOAnand Parikh
IPO DateFeb 4, 2021
Beta-0.30
52-Week Range$7.45 – $42.143
Avg Volume346,875
ExchangeNASDAQ
Websitefaeththerapeutics.com

Ownership

Float71.8%
Shares Outstanding25.8M

Recent Insider Trades

Parikh Anand KiranGIFT
Oct 30, 2026100,000 shares
Parikh Anand KiranGIFT
Oct 30, 2026100,000 shares
Schayowitz AdamAWARD
Oct 23, 202625,000 shares @ $17.08
Schayowitz AdamOTHER
Oct 23, 20260 shares
Vousden Karen HAWARD
Sep 11, 202625,000 shares @ $37.44

Peers

BOLDBoundless Bio, Inc.
$56.0M
JANXJanux Therapeutics, Inc.
$1.08B
KURAKura Oncology, Inc.
$646.7M
KZIAKazia Therapeutics Ltd ADR
$11.6M
NUVBNuvation Bio Inc.
$1.46B
PBYIPuma Biotechnology, Inc.
$425.9M
PRLDPrelude Therapeutics Incorporated
$287.3M
RLAYRelay Therapeutics, Inc.
$4.08B

Recent News

Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
Nov 6, 2026 · businesswire.com
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2026 · businesswire.com
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
Nov 3, 2026 · businesswire.com
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Oct 27, 2026 · businesswire.com
Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib
Oct 23, 2026 · businesswire.com
Data last updated: Nov 9, 2026, 04:11 AM